Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer

International Immunopharmacology(2021)10.1016/j.intimp.2021.108345Source: DataRank Database

A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer is a research paper published in International Immunopharmacology (2021). On theSindex it has a DataRank of 0. It has been cited 35 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access35 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 2.13)OA: greenTopics (50)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Jia Liu ORCID,De Yang ORCID,Debra Tross ORCID,Ping Li ORCID,Fengyang Chen ORCID

Live enrichment

PubMed:34794079 PMC:PMC8665148 OpenAlex:https://openalex.org/W3211409705

Science and Technology Development Fund

Grant: 0056/2019/AFJ

Universidade de Macau

Grant: CPG-CPG2021-00007-ICMS

Universidade de Macau

Grant: MYRG2019-00169-ICMS

Intramural NIH HHS

Grant: Z01 BC009369

Fund for the Development of Science and Technology

National Cancer Institute

National Institutes of Health

Special Fund Project for Science and Technology Innovation Strategy of Guangdong Province

FWCI

2.13

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: https://www.elsevier.com/legal/tdmrep-license

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8665148

publisherhttps://api.elsevier.com/content/article/PII:S1567576921009814?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1567576921009814?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.intimp.2021.108345

Fields of Study

Immune Cell Function and InteractionImmune Response and InflammationImmunotherapy and Immune ResponsesAdjuvants, ImmunologicAnimalsAntibodiesColonic NeoplasmsFemaleFlow CytometryHMGN1 ProteinImidazolesImmunosuppression TherapyLymphocytes, Tumor-InfiltratingMiceMice, Inbred BALB CMice, Inbred C57BLNeoplasm TransplantationReceptors, Tumor Necrosis Factor, Type IIT-Lymphocytes, Regulatory

MeSH Terms

Adjuvants, ImmunologicAnimalsAntibodiesColonic NeoplasmsFemaleFlow CytometryImidazolesImmunosuppression TherapyMice, Inbred BALB CMice, Inbred C57BLNeoplasm TransplantationLymphocytes, Tumor-InfiltratingHMGN1 ProteinReceptors, Tumor Necrosis Factor, Type IIT-Lymphocytes, RegulatoryMice

Keywords

Immune systemImmunotherapyFOXP3TLR7ImmunologyCD8Cancer immunotherapyCancer researchMedicineInnate immune systemToll-like receptorAntitumorTnfr2Cd4(+)foxp3(+) Regulatory T Cells (Tregs)Hmgn1 And R848

Sustainable Development Goals

SDG 0: Good health and well-being

A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer

FAIR Checklist

Authors (10)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)